Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673Phase 3Recruiting
- Sponsor
- Acadia Pharmaceuticals
- Start
- Nov 2023
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of remlifanserin in Alzheimer's disease (AD) (3 arms), sponsored by Acadia Pharmaceuticals. Primary endpoint: Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales at 6 weeks. Started Nov 2023; status: recruiting.
02
Drugs
remlifanserin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06159673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06159673.